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SUMMARY
OBJECTIVES—To assess latent tuberculous infection (LTBI) treatment completion rates in a 
large prospective US/Canada multisite cohort and identify associated risk factors.
METHODS—This prospective cohort study assessed factors associated with LTBI treatment 
completion through interviews with persons who initiated treatment at 12 sites. Interviews were 
conducted at treatment initiation and completion/cessation. Participants received usual care 
according to each clinic’s procedure. Multivariable models were constructed based on stepwise 
assessment of potential predictors and interactions.
RESULTS—Of 1515 participants initiating LTBI treatment, 1323 had information available on 
treatment completion; 617 (46.6%) completed treatment. Baseline predictors of completion 
included male sex, foreign birth, not thinking it would be a problem to take anti-tuberculosis 
medication, and having health insurance. Participants in stable housing who received monthly 
appointment reminders were more likely to complete treatment than those without stable housing 
or without monthly reminders. End-of-treatment predictors of non-completion included severe 
symptoms and the inconvenience of clinic/pharmacy schedules, barriers to care and changes of 
residence. Common reasons for treatment non-completion were patient concerns about 
tolerability/toxicity, appointment conflicts, low prioritization of TB, and forgetfulness.
CONCLUSIONS—Less than half of treatment initiators completed treatment in our multisite 
study. Addressing tangible issues such as not having health insurance, toxicity concerns, and clinic 
accessibility could help to improve treatment completion rates.
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AN ESTIMATED 9–14 million persons in the United States have latent tuberculous 
infection (LTBI) and are therefore at risk for progression to active tuberculosis (TB) 
disease.1 With declining numbers of active TB cases in the United States and Canada, TB 
prevention and care programs increasingly focus on identifying and treating LTBI as key to 
eliminating TB in these countries.2,3 Approximately 300 000 individuals are treated for 
LTBI in the United States annually.4 While the Centers for Disease Control and Prevention 
(CDC) have set a target of 79% completion by 2015,5 actual LTBI treatment completion 
rates in the United States and Canada are generally reported to range from 20% to 65% for a 
6-month course of self-administered treatment, although a few smaller studies have shown 
higher completion rates.6 A large retrospective multisite study recently reported completion 
rates for the standard 9-month isoniazid (INH) regimen ranging from 30% to 60%.7
To move towards TB elimination, TB control efforts in the United States and Canada should 
focus efforts on improving completion of LTBI treatment. Understanding barriers to and 
factors associated with the completion of LTBI treatment will facilitate the development of 
effective, appropriate interventions.
We conducted a large-scale prospective study, guided by a socio-ecological framework,8 of 
individuals offered LTBI treatment in 30 clinics associated with 12 sites (11 US and one 
Canadian) of the Tuberculosis Epidemiologic Studies Consortium (TBESC),9 funded by the 
CDC. This is the third report on the results of this study. Earlier work reported on acceptance 
of LTBI treatment10 and treatment discontinuation due to adverse events.11 In this analysis, 
we assess LTBI treatment completion rates and identify risk factors associated with 
completion/non-completion of LTBI treatment.
MATERIALS AND METHODS
Design, setting, and sample
From March 2007 to September 2008, persons eligible for LTBI treatment according to 
current CDC guidelines on the tuberculin skin test (TST)5 at participating clinics were 
referred by providers to research staff. More details on study design are provided in Colson 
et al.10 and are not repeated here.
The study was approved by the institutional review boards (IRB) of the CDC and the 
oversight committees of jurisdictional entities and study sites. All participants provided 
written informed consent and received usual care according to the standard operating 
procedures of the clinics.
Definitions
Study definition of treatment completion was based on specified number of doses completed 
within a specified time period for each regimen.2 See Pettit et al. for further details.11
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Data were collected through in-person interviews administered by trained study staff when 
participants initiated treatment (baseline) and completed/defaulted from treatment (exit), 
abstraction of data from participants’ medical charts, and clinic surveys. See Colson et al.10 
and Pettit et al.11 for further details on in-person interviews and chart abstraction. At each 
site, the study coordinator and clinic director determined who would complete the clinic 
survey, in which information was collected on clinic population, procedures, and services. 
All data collection instruments underwent pilot testing.
Analysis
A knowledge score was constructed by calculating the mean of correct answers to 
knowledge items. Assessment of problematic drug/alcohol use was based on reported 
symptoms of addiction and use of rehabilitation services. A barriers-to-care scale was 
calculated from eight possible concerns. Acculturation scores were divided into three equal-
sized groups. Student’s t-test was used for continuous variables and χ2 or Fisher’s exact test 
for categorical variables. The Holm-Bonferroni approach was used to adjust for multiple 
comparisons, with the procedure being applied separately to baseline and exit data to assess 
the significance.12 Irrespective of the Holm-Bonferroni criteria, variables with P < 0.10 and 
variables hypothesized a priori to be predictors were candidates for multivariable models. 
The Holm-Bonferroni method was applied separately to each model to assess significance of 
model coefficients. Hierarchical models were used to adjust for clustering by clinic; 
potential predictors were selected for multivariable models using stepwise selection 
methods. Significant interactions were identified using stepwise selection. Two models were 
created: one predicting baseline characteristics associated with treatment completion, 
including clinic characteristics, using binomial regression; and a second to assess factors 
associated with treatment completion at end of treatment. All statistical analyses were 
performed using SAS version 9.2 (Statistical Analysis System, Cary, NC, USA).
RESULTS
Study participants and clinics
Each of the 12 TBESC sites was associated with one to five public health clinics that 
enrolled study participants; enrollment into the larger study is discussed in Colson et al.10 
This analysis follows the 1515 enrollees who accepted LTBI treatment (see Colson et al. for 
an analysis of LTBI treatment acceptance10); of this group, the clinic charts of 192 
participants could not be located, resulting in 1323 participants with evaluable outcomes and 
therefore eligible for the completion analysis. The 192 participants lacking chart information 
were concentrated in two clinics. According to data from the baseline interview, participants 
with missing charts differed from participants with evaluable outcomes as regards sex (more 
females for missing charts), income (lower income), inconvenience in getting to clinic 
(fewer with no inconvenience), and stopping medications if feeling sick (fewer would stop).
The majority of the participants were women, and the mean age was 37.2 years (Table 1). 
Hispanics comprised 31.2% of the sample, Asians 28.9%, and non-Hispanic Blacks 24.5%. 
Approximately three quarters were born outside the United States and Canada.
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Of the 1323 treatment acceptors with evaluable outcomes, 617 (46.6%) completed INH 
treatment; the median completion rate among clinics was 48.4% (interquartile range 35.0–
59.0). Of 1279 study participants who were prescribed 9 months of INH, 595 (46.5%) 
completed treatment. An additional 44 were prescribed 6 months of INH, and 22 (50.0%) 
completed treatment (Figure). Sixty-two (4.7%) participants had a regimen change to 4 
months of rifampin (RMP) during treatment, two were transferred to directly observed 
therapy for LTBI, and two developed active TB. These 66 participants were classified as 
non-completers of self-administered INH treatment. Of the 62 participants who were 
switched to 4 months of RMP, 47 (75.8%) completed treatment.
Baseline predictors of treatment completion
As shown in Table 1, treatment completion rates were strongly associated with race/ethnicity 
(highest for Asians), health insurance (lower for those without), acculturation (lowest for 
US- and Canada-born), drug use (lower for those with past or present drug problems), 
apprehension about medications (‘would stop meds if I feel sick’), the original reason for 
testing (lowest for living situation, highest for visa status/regular check-up), whether clinics 
provided appointment reminders (higher when appointments provided), and whether clinics 
had social workers on site (lower when on site). None of the remaining variables in Table 1 
met the Holm-Bonferroni criterion for significance.
In multivariable analysis, male sex (adjusted risk ratio [aRR] 1.19, 95% confidence interval 
[CI] 1.08–1.31), foreign birth (aRR 1.19, 95%CI 1.07–1.33), and having health insurance 
(aRR 1.24, 95%CI 1.08–1.42) were independent predictors of treatment completion; 
thinking it would be a problem to take TB medication (aRR 0.68, 95%CI 0.50–0.92) was a 
predictor of treatment non-completion (Table 2). There was a significant interaction between 
housing and appointment reminders: participants in stable housing who received monthly 
appointment reminders were more likely to complete than those without stable housing or 
those not receiving reminders (aRR 1.80, 95%CI 1.24–2.61). Knowing that TB is 
transmitted through the air did not meet the Holm-Bonferroni criterion for significance as 
predictors of non-completion. Other predictors significant on univariate analysis were not 
significant on multivariable analysis. In particular, the availability of social workers was not 
significant as an independent predictor in the multivariable analysis. Clinics with social 
workers available either part or all of the time served fewer persons who were foreign-born 
(59.4% vs. 73.3% overall) and populations with less health insurance coverage (55.9% vs. 
59.8% overall), both factors that are represented in the model. The original reason for testing 
was not significant in the multivariable model.
Factors associated with completion at end of treatment
Of the 1323 participants with evaluable outcomes, 939 returned for an exit interview (Table 
3). Completion rates were lower for participants who moved frequently during treatment 
(P=0.0012), who lost their jobs during treatment (P=0.0053), who found the clinic schedule 
‘very inconvenient’ (P=0.0007), or who found getting medications ‘very inconvenient’ (P < 
0.0001). Experiencing severe symptoms strongly predicted non-completion, as only 9.3% of 
those reporting severe symptoms completed treatment (P < 0.0001) vs. 62.9% for those with 
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non-severe symptoms and 69.5% for those with no symptoms. Completers had significantly 
lower scores on the barriers-to-care scale than non-completers (P=0.0001).
Multivariable analysis (Table 4) highlighted severe symptoms and inconvenience of clinic 
and pharmacy schedules to be most strongly associated with treatment non-completion. 
Participants who reported severe symptoms were least likely to complete treatment; among 
those without severe symptoms (i.e., either non-severe or no symptoms), participants who 
reported major inconveniences with medication/clinic schedules appeared to be less likely to 
complete than those with minor inconveniences, but both groups were far more likely to 
complete than those who experienced severe symptoms (P < 0.0001). Barriers to care and 
changes of residence were also associated with non-completion using the Holm-Bonferroni 
criteria.
Reasons for stopping medications
Among participants who did not complete LTBI treatment, the most frequently reported 
reasons for stopping were pill-related (52.5%), with 45.8% reporting tolerability and toxicity 
issues (Table 5). Appointments conflicting with job (6.3%), believing that TB is a low 
priority (4.6%), and believing that medications are not beneficial (4.67%) were other 
reported reasons for stopping treatment.
DISCUSSION
Completion of LTBI treatment benefits both the treated individual and society in general by 
preventing cases of active, infectious TB disease. Understanding factors associated with 
treatment completion and developing interventions to support treatment completion are 
therefore critical to public health policy.13,14 This study was guided by a socio-ecological 
framework, which is based on the premise that multiple levels—individual, interpersonal, 
organizational and community—influence human behavior in different ways and to different 
degrees.8 While not a nationally representative sample, this is a large prospective multisite 
cohort study, including 12 sites and 30 clinics. This represents an advance over the single-
site retrospective studies found in the literature. Furthermore, our study represents a 
substantial contribution to the literature on LTBI, as it is the first time a comprehensive 
approach was taken to gather and analyze information on LTBI treatment regarding 
provider-patient communication, clinic characteristics, and community norms, in addition to 
individual patient behavior and cognition in general clinic populations.
Less than half of those who initiated self-administered INH in this study completed 
treatment, in line with other studies.6,7 Moreover, if one looks at treatment completion 
among those who were prescribed INH, including the 247 who declined LTBI treatment,10 
the completion rate drops to 39% (617/1570). In contrast to Shieh et al.,15 we found a 
number of significant associations between completion and demographic or socio-economic 
characteristics, possibly because of the larger study sample size. At baseline, male sex, 
foreign birth, and health insurance were strongly associated with completion, while drug use 
and concern about side effects (‘would stop meds if feel sick’) were strongly associated with 
non-completion. Previous studies examining sex differences have found contradictory 
results;6 our result reinforces an earlier report that females in LTBI treatment were more 
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likely to discontinue due to adverse effects.11 In unadjusted analysis, both Asian race and 
lower acculturation were associated with higher completion rates; in multivariable analysis, 
foreign birth represents these factors. An earlier report from this study reported higher 
acceptance rates for persons with lower acculturation.10 Health insurance was strongly 
associated with higher completion in both crude and adjusted analyses. Importantly, 
participants in stable housing who attended clinics that sent appointment reminders were 
more likely to complete treatment than those without stable housing or those treated at 
clinics that did not send reminders. Completion rates were substantially lower among 
subjects who reported drug problems; while this group represents a small proportion of the 
study population (7.3%), drug use could be a greater factor in some clinic settings.
A separate model reflecting participants’ experiences while on treatment shows that not 
experiencing severe symptoms, having minimal barriers to care, convenient clinic schedules, 
and not moving during treatment were all independently associated with increased treatment 
completion. An earlier study10 reported that convenience of clinic schedules also affected 
the likelihood of accepting LTBI treatment.
Our study had some limitations. Only one Canadian clinic participated in the study, limiting 
the representation of that region. Most data were collected through face-to-face interviews, 
and self-reporting of some items (e.g., drug/alcohol use) may have been subject to social 
desirability bias. We were also unable to assess outcomes on some participants due to 
missing medical charts; demographic and attitudinal differences identified between these 
participants and those with evaluable outcomes were included as covariates in the predictive 
models. Outcomes could not be determined for a substantial number of participants (n = 
192, 14.5%), as their medical charts could not be located; as there were more females among 
those missing charts than those with charts, and as females were less likely to complete 
treatment, it is possible that our estimated completion rate would have been even lower had 
we been able to locate all the charts. Only 71% of those interviewed at baseline were 
available for the exit interview. Finally, while we collected reasons for individuals who 
refused participation to study staff, we could not do so for individuals who declined to speak 
to clinic staff. Clinic participation was dependent on caseload (i.e., large enough caseload to 
meet target sample sizes) and willingness of clinic staff to participate. As in all clinic-based 
studies, there is the potential for bias in clinic selection. While we found an association 
between appointment reminders and treatment completion, the number of clinics not 
providing reminders was small (3 of 30 participating clinics).
CONCLUSIONS
Our study indicates that completion of LTBI treatment is actually higher among foreign than 
US- and Canada-born persons. Our results also suggest the importance of targeting drug 
users for special outreach efforts to support treatment completion. It is also vital to improve 
the management of side effects; prior to beginning treatment, apprehension about 
medications (‘would stop meds if I feel sick’) was an important predictor of non-completion, 
while experiencing symptoms during treatment was strongly associated with non-completion 
at study exit. TB clinics should provide appointment reminders and maintain schedules that 
accommodate patients’ needs. The cost of TB/LTBI care should not be an impediment; 
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patients should be made aware that they will not be charged if they are unable to pay. 
Finally, efforts should be made to improve communication and coordination across clinics to 
facilitate completion of LTBI treatment for patients when they move.
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Participant flow. LTBI = latent tuberculous infection; INH = isoniazid.
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n (%) P value†
Total 1323 (100.0)   618 (46.7)   705 (53.3)
Demographic characteristics
 Sex   0.0065
  Male   609 (46.0)   309 (50.7)   300 (49.3)
  Female   714 (54.0)   309 (43.3)   405 (56.7)
 Age, years   0.2191
  18–24   243 (18.4   100 (41.2)   143 (58.8
  25–44   697 (52.7   340 (48.8)   357 (51.2)
  45–64   343 (26.0)   160 (46.6)   183 (53.4)
   ⩾65     39 (3.0)     17 (43.6)     22 (56.4)
 Race/ethnicity   0.0017‡
  Hispanic   413 (31.2)   180 (43.6)   233 (56.4)
  Asian   382 (28.9)   212 (55.5)   170 (44.5)
  Black non-Hispanic   324 (24.5)   142 (43.8   182 (56.2)
  White non-Hispanic   126 (9.5)     53 (42.1)     73 (57.9)
  Multiple/unknown     52 (3.9)     24 (46.2)     28 (53.8)
  Native Hawaiian/Pacific Islander     26 (2.0)       7 (26.9)     19 (73.1)
Reason for testing   0.0086
 Non-TB medical condition     28 (2.2)     12 (42.9)     16 (57.1)
 Possible exposure to someone with TB   129 (9.9)     62 (48.1)     67 (51.9)
 Pregnancy or childbirth     99 (7.6)     45 (45.5)     54 (54.5)
 Employment, insurance, school   431 (33.2)   188 (43.6   243 (56.4)
 Living situation (nursing home, homeless shelter, jail, etc.)     51 (3.9     15 (29.4)     36 (70.6)
 Regular check-up   114 (8.8)     57 (50.0)     57 (50.0)
 Referred by another doctor/HCW     62 (4.8)     35 (56.5)     27 (43.5)
 To obtain or change visa status   229 (17.6)   128 (55.9)   101 (44.1)
 Other   157 (12.1)     65 (41.4)     92 (58.6)
HCW   0.5156
 Yes     90 (6.8)     39 (43.3)     51 (56.7)
 No 1233 (93.2)   579 (47.0)   654 (53.0)
Health insurance   0.0011‡
 Yes   781 (59.8)   396 (50.7)   385 (49.3)
 No   526 (40.2)   217 (41.3)   309 (58.7)
Currently homeless   0.0041
 Yes     41 (3.1)     10 (24.4)     31 (75.6)
 No 1279 (96.9)   605 (47.3)   674 (52.7)
Foreign-born   0.0026
 Yes   970 (73.3)   478 (49.3)   492 (50.7)



















n (%) P value†
 No   353 (26.7)   140 (39.7)   213 (60.3)
Acculturation   0.0021‡
 Low   364 (27.6)   189 (51.9)   175 (48.1)
 Moderate   280 (21.3)   124 (44.3)   156 (55.7)
 High   320 (24.3)   163 (50.9)   157 (49.1)
 US- and Canada-born   353 (26.8)   140 (39.7)   213 (60.3)
LTBI history
 Received BCG   0.3640
  Yes   709 (53.6)   333 (47.0)   376 (53.0)
  No   456 (34.5)   204 (44.7)   252 (55.3)
  Don’t know   158 (11.9)     81 (51.3)     77 (48.7)
 Contact with TB case   0.9548
  Yes   130 (9.8)     60 (46.2)     70 (53.8)
  No/unknown 1193 (90.2)   558 (46.8)   635 (53.2)
Current alcohol use   0.0191
 Yes   444 (33.6)   187 (42.1)   257 (57.9)
 No   879 (66.4   431 (49.0)   448 (51.0)
Drug use <0.0001‡
 Current problem     62 (4.7)     15 (24.2)     47 (75.8)
 Prior problem     35 (2.7)       8 (22.9)     27 (77.1)
 No history of problem   169 (12.8)     79 (46.7)     90 (53.3)
 Never used 1054 (79.9)   515 (48.9   539 (51.1
How inconvenient was getting to the clinic today?   0.0142
 Not inconvenient   832 (63.0)   410 (49.3)   422 (50.7)
 A little inconvenient   370 (28.0)   164 (44.3   206 (55.7)
 Very inconvenient   119 (9.0)     43 (36.1)     76 (63.9)
How inconvenient was the clinic schedule?   0.0199
 Not inconvenient   983 (74.6)   474 (48.2)   509 (51.8)
 A little inconvenient   229 (17.4     89 (38.9)   140 (61.1)
 Very inconvenient   106 (8.0)     55 (51.9)     51 (48.1)
Knowledge and attitudes
 Would stop medications if feel sick <0.0001‡
  Yes   788 (65.6)   333 (42.3)   455 (57.7)
  No   413 (34.4)   224 (54.2)   189 (45.8)
 Would stop medications to use alcohol       0.0037
  Yes     24 (1.8)       6 (25.0)     18 (75.0)
  No   814 (62.1)   363 (44.6)   451 (55.4)
  Does not drink alcohol   472 (36.0)   244 (51.7)   228 (48.3)
Clinic characteristics
 Clinic routinely provides reminders for follow-up visits <0.0001‡
  Yes, to all patients 1004 (76.4)   505 (50.3)   499 (49.7)



















n (%) P value†
  Yes, to some patients   215 (16.4)     86 (40.0)   129 (60.0)
  No, to all patients     96 (7.3)     24 (25.0)     72 (75.0)
 Clinic charges for services       0.1234
  Some charges   723 (55.0)   352 (48.7)   371 (51.3)
  No charges   592 (45.0)   263 (44.4)   329 (55.6)
 On-site social worker is available <0.0001‡
  Always   106 (8.1)     37 (34.9)     69 (65.1)
  Sometimes   266 (20.2)   102 (38.3   164 (61.7)
  Not available   943 (71.7)   476 (50.5)   467 (49.5)
*
Data in this table were presented in a different format and for a slightly different study population in Pettit et al.11
†
P values give significance values for χ2 tests of association between the characteristics shown at left and completion of LTBI treatment.
‡
P values meeting the Holm-Bonferroni significance criterion with α = 0.05.
LTBI = latent tuberculous infection; HCW = health care worker; BCG = bacille Calmette-Guérin; TB = tuberculosis.
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Table 2
Multivariable regression of baseline predictors of treatment completion
Parameter Regression coefficient Standard error RR (95%CL) P value
Intercept −1.4831   0.2102 — <0.0001*
Male sex   0.1714   0.0483 1.187 (1.08–1.31)   0.0004*
Foreign-born   0.1767   0.0569 1.193 (1.07–1.33)   0.0019*
Health insurance   0.2147   0.0702 1.240 (1.08–1.42)   0.0022*
Know that TB is transmitted through air −0.1729   0.0784 0.841 (0.72–0.98) 0.0275
Think that taking TB meds would be a problem −0.3927   0.1558 0.675 (0.50–0.92)   0.0118*
Current homelessness/clinic reminders
 Not homeless and clinic sends reminders to all/some patients   0.5868   0.1892 1.798 (1.24–2.61)   0.0019*
 Not homeless and clinic sends reminders to no patients −0.0297   0.2552 0.971 (0.59–1.60) 0.9075
 Currently homeless Reference — — —
*
P values meeting the Holm-Bonferroni significance criterion with α = 0.05.
RR = risk ratio; CL = confidence limit; TB = tuberculosis.
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Table 3




n (%) P value
Total        554        385
Currently homeless   1.0000
 Yes       7 (58.3)       5 (41.7)
 No   547 (59.0)   380 (41.0)
Number of times moved   0.0012*
 0   395 (62.5)   237 (37.5)
 1   121 (56.3)     94 (43.7)
  ⩾2     38 (41.8)     53 (58.2)
Lost job because of tuberculosis   0.0053*
 Yes       2 (22.2)       7 (77.8)
 No   499 (62.0)   306 (38.0)
 Not applicable     50 (50.5)     49 (49.5)
Comfortable with language used by health care provider   0.5817
 Yes   544 (58.9)   380 (41.1)
 No       9 (69.2)       4 (30.8)
How inconvenient was the clinic schedule?   0.0007*
 Not inconvenient   382 (61.0)   244 (39.0)
 A little inconvenient   139 (61.0)     89 (39.0)
 Very inconvenient     33 (38.8)     52 (61.2)
How inconvenient was getting the medications? <0.0001*
 Not inconvenient   437 (61.8)   270 (38.2)
 A little inconvenient     98 (60.5     64 (39.5)
 Very inconvenient     18 (27.3)     48 (72.7)
Quantity of pills taken† <0.0001*
 All   456 (75.0)   152 (25.0)
 Most     96 (46.2   112 (53.9
 Some/few       2 (2.0)     98 (98.0)
Symptoms experienced <0.0001*
 Severe symptoms     10 (9.3)     99 (90.7)
 Non-severe symptoms   173 (62.9)   102 (37.1)
 No symptoms   370 (69.5)   162 (30.5)
Barriers to care, mean ± SD‡ 1.40 ± 0.46 1.52 ± 0.49   0.0001*
*




Including transportation, time off, child care, appointments, waiting time, language, cultural familiarity, running into familiar people; lower score 
is better.
SD = standard deviation.
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Table 4
Multivariable regression of end-of-study characteristics of treatment completion based on exit interviews
Parameter Regression coefficient Standard error OR (95%CL) P value
No severe symptoms experienced
 Big inconvenience in clinic schedule, getting medications, 
or both
  2.0245 0.4114 7.572 (3.38–16.98) <0.0001*
 No/minor inconvenience in clinic schedule, getting 
medications, or both
  3.0179 0.3468 20.449 (10.35–40.39) <0.0001*
Severe symptoms experienced Reference — — —
Barriers to care scale (per unit change, from 1 to 3) −0.4101 0.1652 0.664 (0.48–0.92)   0.0132*
Number of times moved (per move) −0.2082 0.0912 0.812 (0.68–0.97)   0.0226*
*
P values meeting the Holm-Bonferroni significance criterion with a = 0.05.
OR = odds ratio; CL = confidence limit.
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Table 5
Reasons for stopping treatment*
n (%)†
Economic and structural factors   30 (10.6)
 Financial reasons or fears     1 (0.4)
 Appointments conflict with job   18 (6.3)
 Appointments conflict with family obligations     8 (2.8)
 Housing problems/instability     3 (1.1)
Patient attitudes/personal factors   53 (18.7)
 TB low priority compared to other things   13 (4.6)
 Anti-tuberculosis drugs not beneficial   13 (4.6)
 Perceived low risk of getting TB     2 (0.7)
 Doesn’t understand reason for medication     7 (2.5)
 Sick or ill with other illnesses   10 (3.5)
 Drug/alcohol abuse     1 (0.4)
 Don’t believe they have LTBI     7 (2.5)
Pill-related difficulties 149 (52.5)
 Can’t remember to take pills   16 (5.6)
 Don’t like taking pills     1 (0.4)
 Hard to swallow     2 (0.7)
 Tolerability and toxicity issues (side effects, etc.) 130 (45.8)
Patient-provider relationships   16 (5.6)
 Negative experience with provider(s) (general)     3 (1.1)
 Negative attitude toward LTBI treatment (general)     7 (2.5)
 Poor communication with provider(s)     5 (1.8)
 Lack of confidence/trust in health care system     1 (0.4)
Pattern of health care delivery   25 (8.8)
 Inaccessible clinic location   14 (4.9)
 Inconvenient clinic hours     6 (2.1)
 Long waiting times     2 (0.7)
 Unavailability/inaccessibility of other health or social services     3 (1.1)
 Other   72 (25.4)
 Total reporting a reason 284 (100)
*
Of 989 participants in the analysis data set with an exit DCI, 12 reported never starting their medication and 325 reported stopping their 
medication prior to completion of treatment; 284 of the latter gave one or more reasons for stopping medication.
†
The percentages are based on the numbers shown in the ‘total reporting a reason’ row. Respondents could report more than one reason for 
stopping medication, so the ‘count’ column totals more than the 284 who reported one or more reasons. Similarly, the ‘per cent’ column totals more 
than 100%.
TB = tuberculosis; LTBI = latent tuberculous infection; DCI = data collection instrument.
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